Off-Label Promotion of Prescription Medicine: Is It Ever Justifiable?

Therapeutic Innovation and Regulatory Science

Volumn 49, Issue 3, 2015, Pages 359-363

  Ghinea, Narcyz ^a   Lipworth, Wendy ^b   Kerridge, Ian ^b  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

misbranding; off label; pharmaceutical industry; prescribing; promotion; regulation

Indexed keywords

GENTAMICIN; MORPHINE; PRESCRIPTION DRUG; RITUXIMAB; VALPROIC ACID;

ARTICLE; CLINICAL RESEARCH; DECISION MAKING; DRUG EFFICACY; DRUG INDUSTRY; DRUG MARKETING; DRUG SAFETY; DYSPNEA; EVIDENCE BASED MEDICINE; HEALTH CARE; HEALTH CARE PERSONNEL; HEALTH CARE SYSTEM; HUMAN; MIGRAINE; OFF LABEL DRUG USE; PALLIATIVE THERAPY; PATIENT CARE; PRESCRIPTION; PRIORITY JOURNAL; PUNISHMENT; RESPONSIBILITY; RHEUMATOID ARTHRITIS; STANDARD;

EID: 84930390795     PISSN: 21684790     EISSN: 21684804     Source Type: Journal    
DOI: 10.1177/2168479015570337     Document Type: Article

References (34)

1. US Department of Justice. Eli Lilly and Company agrees to pay $1.415 billion to resolve allegations of off-label promotion of Zyprexa. 2009. Available at:http://www.justice.gov/archive/opa/pr/2009/January/09-civ-038.html.
2. US Department of Justice. Justice Department announces largest health care fraud settlement in its history. 2009. Available at:http://www.justice.gov/opa/pr/justice-department-announces-largest-health-care-fraud-settlement-its-history.
3. US Department of Justice. GlaxoSmithKline to plead guilty and pay $3 billion to resolve fraud allegations and failure to report safety data. 2012. Available at:http://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report.
4. US Department of Justice. Johnson & Johnson to pay more than $2.2 billion to resolve criminal and civil investigations. 2013. Available at:http://www.justice.gov/opa/pr/johnson-johnson-pay-more-22-billion-resolve-criminal-and-civil-investigations.
5. Wellman-Labadie O,Zhou Y.The US orphan drug act: rare disease research stimulator or commercial opportunity?.Health Policy. 2010;95:216-228
6. Steinman MA,Bero LA,Cherin MM,Landefeld CS.Narrative review: the promotion of gabapentin: an analysis of internal industry documents.Ann Intern Med. 2006;145:284-293
7. Spielmans GI,Parry PI.From evidence-based medicine to marketing-based medicine: evidence from internal industry documents.J Bioethical Inquiry. 2010;7:13-29
8. ThomasK. Ruling is victory for drug companies in promoting medicine for other uses. New York Times. 2012. Available at:http://www.nytimes.com/2012/12/04/business/ruling-backs-drug-industry-on-off-label-marketing.html?_r=1&.
9. European Federation of Pharmaceutical Industries and Associations. Position paper: promotion of off-label use of medicines by European healthcare bodies in indications where authorised medicines are available. 2014. Available at:http://www.efpia.eu/uploads/EFPIA_Position_Paper_Off_Label_Use_May_2014.pdf.
10. Radley DC,Finkelstein SN,Stafford RS.Off-label prescribing among office-based physicians.Arch Intern Med. 2006;166:1021-1026
11. Soares M.“Off-label” indications for oncology drug use and drug compendia: history and current status.J Oncol Pract. 2005;1:102-105
12. Bazzano ATF,Mangione-Smith R,Schonlau M,Suttorp MJ,Brook RH.Off-label prescribing to children in the United States outpatient setting.Acad Pediatr. 2009;9:81-88
13. Fisk NM,Atun R.Market failure and the poverty of new drugs in maternal health.PLOS Med. 2008;5:e22
14. Logan AC,Yank V,Stafford RS.Off-label use of recombinant factor VIIa in U.S. hospitals: analysis of hospital records.Ann Intern Med. 2011;154:516-522
15. Donovan PJ,Iedema J,McLeod DS,Kubler P,Pillans P.Off-label use of recombinant factor VIIa in two tertiary hospitals in Queensland.ANZ J Surg. 2013;83:149-154
16. DeMonaco HJ,Ali A,Hippel EV.The major role of clinicians in the discovery of off-label drug therapies.Pharmacotherapy. 2006;26:323-332
17. Chen DT,Wynia MK,Moloney RM,Alexander GC.U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey.Pharmacoepidemiol Drug Saf. 2009;18:1094-1100
18. Largent EA,Miller FG,Pearson SD.Going off label without venturing off course: evidence and ethical off-label prescribing.Arch Intern Med. 2009;169:1745-1747
19. Ghinea N,Lipworth W,Little M,Kerridge I,Day R.Overcoming entrenched disagreements: the case of misoprostol for post-partum haemorrhage [published online ahead of print November 8, 2013].Developing World Bioethics.:
20. Levi M,Levy JH,Andersen HF,Truloff D.Safety of recombinant activated factor VII in randomised clinical trials.N Engl J Med. 2010;363:1791-1800
21. Brody HHooked: Ethics, the Medical Profession, and the Pharmaceutical Industry. Lanham, MD: Rowman & Littlefield; 2007:
22. Hebert PC,Stanbrook MB.Indication creep: physician beware.CMAJ. 2007;177:697
23. Mackey T,Liang BA.Off-label promotion reform: a legislative proposal addressing vulnerable patient drug access and limiting inappropriate pharmaceutical marketing.Univ Mich J Law Reform. 2011;45:1-54
24. Klein DB,Tabarrok A.Do off-label drug practices argue against FDA efficacy requirements? A critical analysis of physicians’ argumentation for initial efficacy requirements.Am J Economics Sociol. 2008;67:743-775
25. Ratner M,Gura T.Off label or off limits?.Nat Biotechnol. 2008;26:867-875
26. DuckettSMcGanninC. Tough choices: how to rein in Australia’s rising health bill. Conversation. 2013. Available at:http://theconversation.com/tough-choices-how-to-rein-in-australias-rising-health-bill-13658.
27. Gillick MR.Controlling off-label medication use.Ann Intern Med. 2009;3:344-347
28. Avorn J,Kesselheim A.A hemorrhage of off-label use.Ann Intern Med. 2011;154:566-567
29. Danes I,Agusti A,Vallano A, et al.Outcomes of off-label drug uses in hospitals: a multicentric prospective study.Eur J Clin Pharmacol. 2014;:
30. National Center for Advanced Translation Science. FAQ about rare diseases. Available at:http://www.ncats.nih.gov/about/faq/rare/rare-faq.html. Accessed October 23, 2014.
31. European Organisation for Rare Diseases. Rare diseases: understanding the public health priority. 2005. Available at:http://www.eurordis.org/IMG/pdf/princeps_document-EN.pdf.
32. U.S. Food and Drug Administration. Novel new drugs 2013 summary. 2014. Available athttp://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM381803.pdf.
33. Council of Australian Therapeutic Advisory Groups. Rethinking medicines decision-making in Australian Hospitals. 2013. Available at:http://www.catag.org.au/rethinking-medicines-decision-making-2/.
34. Psychiatry. 2009;6:43-44